이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

2026년 11월 11일 업데이트: Fujian Cancer Hospital

This is a single-arm, phase II clinical study. A total of 43 treatment-naive hepatocellular carcinoma patients with portal vein tumor thrombus (PVTT) are planned to be enrolled. Eligible subjects will enter the study after signing informed consent.

Each subject will receive TAE-HAIC combined with Iparomlimab and Tuvonralimab (QL1706, 7.5 mg/kg, iv, Q3W) and lenvatinib (8 mg for body weight <60 kg, or 12 mg for body weight >60 kg, po, QD). QL1706 is administered on Day 2 of interventional therapy, with a 21-day cycle. Lenvatinib is taken orally on the day of discharge after QL1706 infusion. The HAIC cycles will be determined by investigators according to the subject's condition, ranging from 3 to 6 cycles.

QL1706 and lenvatinib can be maintained for up to 2 years, until disease progression (PD, comprehensively assessed by investigators based on imaging and clinical status), loss of clinical benefit, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or other treatment discontinuation criteria specified in the protocol, whichever occurs first. For subjects withdrawn due to PD, subsequent treatment options may include targeted agents (apatinib, regorafenib, ramucirumab), immunotherapy (pembrolizumab, camrelizumab, tislelizumab), traditional Chinese medicine preparations with indications for hepatocellular carcinoma, best supportive care or palliative care, in accordance with the 2025 CSCO or NCCN guidelines, at the investigator's discretion.

Contrast-enhanced CT or MRI (PET-CT when necessary) will be performed every 6 weeks (±7 days) from treatment initiation for efficacy assessment until PD, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy or other protocol-specified discontinuation reasons, whichever comes first. Subjects will continue safety visits and survival follow-up after treatment discontinuation. Safety follow-up lasts for 30 days after the last dose (90 days for immune-related adverse events). Survival follow-up is conducted every 3 months within 2 years and every 6 months thereafter up to 3 years after treatment discontinuation or death. For subjects stopping treatment for reasons other than PD or death, tumor progression follow-up including serum tumor markers (AFP, PIVKA-II (DCP)) and imaging examinations (dynamic contrast-enhanced MRI/CT of abdomen and pelvis) will be arranged.

TAE: particulate embolic agents such as gelatin sponge particles, blank microspheres and PVA particles are used to embolize tumor feeding arteries.

HAIC-FOLFOX regimen: oxaliplatin 85 mg/m² intra-arterial infusion over 2-3 h, leucovorin 400 mg/m² intra-arterial infusion over 1-2 h, fluorouracil 400 mg/m² intra-arterial bolus followed by continuous intra-arterial infusion of 2400 mg/m² for 23 h or 46 h, repeated every 3 weeks.

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

43

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Zhuting Fang, MD
  • 전화번호: +8613805012709
  • 이메일: 470389481@qq.com

연구 장소

    • Fujian
      • Fuzhou, Fujian, 중국
        • Fujian Cancer Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged between 18 and 75 years inclusive.

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and Child-Pugh score ≤ 7.

  • Diagnosed by imaging or histopathology with BCLC stage C hepatocellular carcinoma complicated with portal-vein tumor thrombus (Vp1-4); extrahepatic metastases are permitted. The primary lesion is deemed unresectable by multidisciplinary team (MDT) assessment.

  • At least one measurable lesion according to RECIST 1.1 (longest diameter ≥ 10 mm for measurable lesion on spiral CT, or short-axis diameter ≥ 15 mm for malignant lymph node).

  • No prior systemic or locoregional therapies for hepatocellular carcinoma, including but not limited to chemotherapy, targeted therapy, immunotherapy, radiotherapy, surgery, hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), etc.

  • Expected survival ≥ 3 months.

  • Laboratory values obtained within 7 days prior to first study drug administration meet the following criteria (no blood products, hematopoietic growth factors, albumin, or other corrective therapies judged by the investigator permitted within 14 days before laboratory testing):

    1. Biochemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 5 × upper limit of normal (ULN); total serum bilirubin (TBIL) ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min (calculated by the Cockcroft-Gault formula); serum albumin ≥ 30 g/L.
    2. Hematology: hemoglobin (Hb) ≥ 9.0 g/dL; no red-blood-cell transfusion within 1 week (including the day of baseline Hb testing); absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count ≥ 75 × 10⁹/L; no platelet transfusion within 1 week (including the day of baseline platelet testing).
    3. Coagulation: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (i.e., no bleeding episode in the preceding 14 days), the investigator shall confirm that INR falls within a safe and effective therapeutic range.
    4. Urinalysis: urine protein < 2+ by dipstick or routine urinalysis; if urine protein ≥ 2+, 24-hour urinary protein quantification must be < 1 g/24 h.
  • No contraindications to chemotherapy, targeted agents or immunotherapy.

  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days before enrollment, and agree to use reliable effective contraception throughout the study and for 3 months after the last study-drug dose. Male subjects with partners of child-bearing potential must agree to use reliable effective contraception throughout the study and for 3 months after the last study-drug dose. Lactating women are excluded.

  • The subject must be informed of the study prior to trial participation, voluntarily provide written informed consent, and be willing and able to comply with scheduled visits, treatment regimens, laboratory tests and other study-required procedures.

Exclusion Criteria:

  • Diffuse hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, etc., confirmed by imaging or cytology.
  • Any prior history of immunotherapy with any of the following: grade 3 or higher immune-related adverse events (irAEs); toxicities that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapy; disease progression assessed to occur within ≤ 3 months during previous immunotherapy.
  • Received treatment from another clinical trial within 4 weeks prior to the first study-drug administration, unless it is an observational (non-interventional) clinical trial or the subject is in the follow-up phase of an interventional trial; or received locoregional or systemic anti-cancer therapy within 28 days before the first study-drug administration.
  • History of allogeneic bone marrow transplantation or solid-organ transplantation, or active chronic graft-versus-host disease.
  • Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Subjects with asymptomatic mild pleural effusion, ascites or pericardial effusion identified by imaging are eligible.
  • Presence of hepatic encephalopathy or central nervous system metastases.
  • For subjects positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb): HBV-DNA must be < 1 × 10⁴ copies/mL or 2000 IU/mL. Subjects with active hepatitis B must have received antiviral therapy for at least 14 days prior to enrollment (local standard-of-care agents such as entecavir or tenofovir are permitted), and agree to continue effective antiviral therapy during the study. HBV-DNA levels shall be monitored throughout treatment; antiviral therapy must be initiated once HBV-DNA turns positive and shall be maintained during the study and for 6 months after the last study-drug dose. Subjects positive for HCV antibody must undergo HCV-RNA testing; subjects with HCV-RNA > 1 × 10³ copies/mL are excluded.
  • History of esophageal or gastric variceal bleeding secondary to portal hypertension within the preceding 6 months; subjects judged by the investigator to be at high bleeding risk. Any life-threatening bleeding event within the preceding 3 months, including bleeding requiring transfusion, surgery, locoregional intervention, or ongoing medical management.
  • History of arterial or venous thromboembolic events within the preceding 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep-vein thrombosis, or any other serious thromboembolic event. Thrombosis related to implantable venous access ports or catheters, or superficial venous thrombosis stabilized under routine anticoagulation are excluded from this criterion. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is allowed.
  • Continuous use of aspirin (> 325 mg/day) or other known platelet-function inhibitors such as clopidogrel or ticlopidine within 2 weeks prior to first study-drug dose; known severe bleeding diathesis or coagulopathy; or ongoing thrombolytic therapy.
  • Abdominal wall fistula or gastrointestinal perforation, refractory non-healed gastric ulcer, active gastrointestinal bleeding, or definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, faecal occult blood ≥ 2+) without targeted therapeutic intervention within 6 months before enrollment.
  • Uncontrolled comorbidities, including but not limited to: persistent or active infection; symptomatic congestive heart failure (NYHA class II-IV with left-ventricular ejection fraction (LVEF) < 50% on echocardiogram); uncontrolled diabetes; uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite optimal medical therapy, history of hypertensive crisis or hypertensive encephalopathy); clinically significant cardiovascular disease; symptomatic or poorly controlled arrhythmias (congenital long-QT syndrome or corrected QTc > 500 ms calculated by Fridericia formula at screening); active interstitial lung disease or other pulmonary disorders with severe impairment of pulmonary function; history of nephropathy or nephrotic syndrome; severe chronic gastrointestinal disease accompanied by diarrhoea; or psychiatric/social conditions that may impair adherence to study procedures, substantially increase adverse-event risk, or compromise the subject's ability to provide written informed consent.
  • History of active primary immunodeficiency; human immunodeficiency virus (HIV) infection; active syphilis infection.
  • Active or clinically uncontrolled severe infection. Severe infection occurring within 4 weeks before first study-drug administration, including but not limited to hospitalization for infectious complications, sepsis, severe pneumonia, and active tuberculosis (currently receiving anti-tuberculosis therapy or having received anti-tuberculosis therapy within 1 year before first dosing).
  • Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, immunosuppressants) within 2 years prior to first study-drug administration. Replacement therapies (e.g., thyroxine, insulin, physiological-dose corticosteroids for adrenal or pituitary insufficiency) are permitted. For subjects with positive autoantibodies only, the investigator must confirm the absence of clinical autoimmune disease. Use of immunosuppressive agents within 4 weeks before first dosing is excluded, except for intranasal, inhaled or other topical corticosteroids, or physiologic-dose systemic corticosteroids (i.e., ≤ 10 mg prednisone per day or equivalent).
  • Received live-attenuated vaccine within 4 weeks prior to first study-drug administration, or planned to receive live-attenuated vaccine during the study.
  • Major surgery (craniotomy, thoracotomy, laparotomy) performed within 4 weeks before first study-drug administration, or unhealed wounds, ulcers or fractures; tissue biopsy or venepuncture for intravenous infusion are exempted.
  • Diagnosis of other malignant neoplasms within 5 years prior to first study-drug administration, except for basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or radically resected carcinoma in-situ.
  • Known hypersensitivity to any study drug or any of its excipients.
  • Pregnant or lactating women.
  • Any other condition rendering the subject unsuitable for participation in this study, as judged by the investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental

TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate
기간: From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

Percentage of participants achieving objective response (CR or PR) maintained for at least 4 weeks assessed per mRECIST

From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of Response
기간: From first study treatment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from first documented objective response to disease progression or death

From first study treatment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)
Disease Control Rate
기간: From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

Percentage of participants achieving disease control (CR or PR or SD) maintained for at least 4 weeks assessed per mRECIST

From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first
Progression-Free Survival
기간: From enrollment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from enrollment to first-documented disease progression per mRECIST or death from any cause, whichever occurs first

From enrollment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)
Overall Survival
기간: From enrollment until death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from enrollment to death from any cause

From enrollment until death from any cause (maximum participant follow-up 3 years after end of treatment)
Incidence and severity of adverse events
기간: From first study treatment through 30 days after last study-drug dose; immune-related adverse events followed through 90 days after last study-drug dose

Treatment-emergent adverse events graded by CTCAE v5.0, including immune-related adverse events

From first study treatment through 30 days after last study-drug dose; immune-related adverse events followed through 90 days after last study-drug dose

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 1일

기본 완료 (추정된)

2030년 3월 1일

연구 완료 (추정된)

2030년 9월 1일

연구 등록 날짜

최초 제출

2026년 11월 11일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant-level data (IPD) will not be shared. This is a single-site, investigator-initiated exploratory phase II study. Access to individual-level participant data is restricted per institutional data governance requirements and local patient-privacy regulations. Data sharing outside of the approved study scope is not pre-planned for this trial.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다